The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis.

BACKGROUND Antipsychotic drugs are used in the routine treatment of adults with intellectual disabilities (ID) and challenging behaviour in the UK despite limited evidence of their effectiveness. There is no evidence on their cost-effectiveness. METHODS The relative cost-effectiveness of risperidone, haloperidol and placebo in treating individuals with an ID and challenging behaviour was compared from a societal perspective in a 26-week, double-blind, randomised controlled trial. Outcomes were changes in aggression and quality of life. Costs measured all service impacts and unpaid caregiver inputs. RESULTS After 26 weeks, patients randomised to placebo had lower costs compared with those in the risperidone and haloperidol treatment groups. Aggression was highest for patients treated with risperidone and lowest for patients treated with haloperidol; however, quality of life was lowest for patients treated with haloperidol and highest for patients treated with risperidone. CONCLUSION The treatment of challenging behaviour in ID with antipsychotic drugs is not a cost-effective option.

[1]  D. Murphy,et al.  Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial , 2008, The Lancet.

[2]  P. Jones,et al.  Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. , 2007, The British journal of psychiatry : the journal of mental science.

[3]  M. Beneke,et al.  Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours: discontinuation study. , 2007, The British journal of psychiatry : the journal of mental science.

[4]  J. Lieberman,et al.  Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. , 2006, The American journal of psychiatry.

[5]  K. Schulman,et al.  Analytic considerations in economic evaluations of multinational cardiovascular clinical trials. , 2006, Value in Health.

[6]  Elisabeth Fenwick,et al.  A guide to cost-effectiveness acceptability curves. , 2005, The British journal of psychiatry : the journal of mental science.

[7]  Andrew R Willan,et al.  Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. , 2005, American heart journal.

[8]  G. Remington,et al.  Healthcare resource utilization during 1‐year treatment with long‐acting, injectable risperidone , 2004, Pharmacoepidemiology and drug safety.

[9]  A. Dubini,et al.  Depression in the Italian community: epidemiology and socio-economic implications , 2004, International clinical psychopharmacology.

[10]  Anita Patel,et al.  The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care , 2004, International clinical psychopharmacology.

[11]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[12]  P. Harris,et al.  Challenging behaviour in community services. , 2001, Journal of intellectual disability research : JIDR.

[13]  D. Felce,et al.  Reducing antipsychotic medication in people with a learning disability , 2000, British Journal of Psychiatry.

[14]  L. Duggan,et al.  Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomized controlled trials. , 2001, Journal of intellectual disability research : JIDR.

[15]  A. Mortimer,et al.  Prospective study into factors associated with aggressive incidents in psychiatric acute admission wards , 1998, British Journal of Psychiatry.

[16]  M. Reichman,et al.  Rating aggression in the clinical setting. A retrospective adaptation of the Overt Aggression Scale: preliminary results. , 1991, The Journal of neuropsychiatry and clinical neurosciences.

[17]  R. Pruchno.  The Effects of Help Patterns on the Mental Health of Spouse Caregivers , 1990, Research on aging.

[18]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[19]  M. Aman,et al.  The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. , 1985, American journal of mental deficiency.